Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01322737 · ClinicalTrials.gov registry record · NA

Feasibility Trial to Evaluate the Ability of the SuMO Tissue Access and Resection System

A NA study of Gastric Disease and Colon Disease, sponsored by University Hospitals Cleveland Medical Center.

Completed
Registry status
NA
Development phase
9
Enrollment target
1
Study location

NCT01322737: Completed NA study of Gastric Disease and Colon Disease, sponsored by University Hospitals Cleveland Medical Center.

NCT01322737 is a NA study of Gastric Disease and Colon Disease that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01322737, a NA study of Gastric Disease and Colon Disease, has completed, sponsored by University Hospitals Cleveland Medical Center.

COMPLETED
Registry status
NA
Development phase
9 participants
Enrollment target
1
Study location

Study Summary

This feasibility trial will evaluate the ability of the SuMO Tissue Access and Resection System (Apollo Endosurgery, Austin, Texas). The SuMO System utilizes balloons to create a submucosal pocket and electrosurgical cutting device to resect the mucosa. The SuMO elevates the tissue from the underlying muscularis using a balloon to distend the submucosa, similar to what is currently performed with injectable saline in a standard EMR. After dissection of the lesion, a separate cutting device will be utilized to resect the tissue by cutting around the border of the targeted tissue. If needed, a standard loop snare will be used to complete the mucosal resection.

Primary Outcome

Assess the feasibility of the SuMO device for creation of a submucosal pocket and resecting the overlying mucosa in a segment of excised human colon or stomach.

Interventions

  • PROCEDURE Tissue Access and Resection System

Study Locations (1)

Ohio

  • University Hospitals Case Medical Center - Cleveland

Trial Details

FieldValue
Enrollment Target 9 participants
Start Date 2011-01
Est. Completion 2011-06
Phase NA

What the finished NCT01322737 record still lists

NCT01322737 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 2 conditions, with Gastric Disease appearing as the primary indexed condition, and to 1 intervention - of which Tissue Access and Resection System is the first listed.

NCT01322737 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT01322737 about?

NCT01322737 is a clinical study titled "Feasibility Trial to Evaluate the Ability of the SuMO Tissue Access and Resection System". This feasibility trial will evaluate the ability of the SuMO Tissue Access and Resection System (Apollo Endosurgery, Austin, Texas). The SuMO System utilizes balloons to create a submucosal pocket and electrosurgical cutting device to resect the mucosa. The SuMO elevates the tissue from the underlyi...

What is the current status of trial NCT01322737?

This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2011-01. Estimated completion is 2011-06.

What conditions does trial NCT01322737 study?

This clinical trial studies the following conditions: Gastric Disease, Colon Disease.

What interventions are being tested in trial NCT01322737?

The interventions under investigation include: Tissue Access and Resection System (PROCEDURE).

Who is sponsoring clinical trial NCT01322737?

This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01322737 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastric Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01322737's enrollment target sits among peer trials

9 1975th of 2000 higher than 25 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01322737, the US trial registry maintained by the National Library of Medicine. NCT01322737 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.